A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Nkure Therapeutics and Crispr Therapeutics partner to develop off-the-shelf CAR T therapy for oncology in India.

NKure Therapeutics & CRISPR Therapeutics partner to advance CTX112 for cancer treatment in India: Our Bureau, Bengaluru Wednesday, May 7, 2025, 13:45 Hrs [IST] NKure Therapeutics, ...

The development paves the way to launch of commercial production of medicines, tentatively starting July 2025.

potentially overcoming limitations associated with current cell surface-targeting immunotherapies. The phase 1 study (NCT04426669) evaluated the effects of administering autologous neoantigen-reactive ...

The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

A first-in-human clinical trial tests a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) cancers.

Beam Therapeutics and Verve Therapeutics have each built their lead candidates on a technique billed as a safer alternative ...

Researchers at the University of Minnesota have completed a first-in-human clinical trial testing a CRISPR/Cas9 gene-editing technique to help the immune system fight advanced gastrointestinal (GI) ...

CTX001 is an ‘ex vivo’ application of gene-editing, in which the technology is used to modify a patient’s own cells outside the body. It uses CRISPR/Cas9 to make a patient’s haematopoietic ...

The BRILLIANCE study of EDIT-101 in Leber congenital amaurosis type 10 (LCA10) – an inherited form of blindness – was reported to be the first 'in vivo' CRISPR/Cas9 medicine to be administered ...